Amanda Elizabeth Inn Proudfoot

Amanda Elizabeth Inn Proudfoot's AcademicInfluence.com Rankings

Chemistry

#4279

World Rank

#5348

Historical Rank

chemistry Degrees

Amanda Elizabeth Inn Proudfoot

Biology

#11805

World Rank

#15229

Historical Rank

Molecular Biology

#1858

World Rank

#1887

Historical Rank

Biochemistry

#1973

World Rank

#2114

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

Amanda Elizabeth Inn Proudfoot's Degrees

PhD Biochemistry Stanford University
Bachelors Chemistry University of California, Berkeley

Why Is Amanda Elizabeth Inn Proudfoot Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Amanda Elizabeth Inn Proudfoot's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines (2003) (813)
Chemokine receptors: multifaceted therapeutic targets (2002) (723)
Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice (2008) (647)
International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors (2014) (629)
Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. (1997) (628)
RANTES Deposition by Platelets Triggers Monocyte Arrest on Inflamed and Atherosclerotic Endothelium (2001) (603)
The Coordinated Action of CC Chemokines in the Lung Orchestrates Allergic Inflammation and Airway Hyperresponsiveness (1998) (594)
Lymph-Borne Chemokines and Other Low Molecular Weight Molecules Reach High Endothelial Venules via Specialized Conduits While a Functional Barrier Limits Access to the Lymphocyte Microenvironments in Lymph Node Cortex (2000) (589)
Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. (1999) (574)
CC Chemokine Receptor (CCR)4 and the CCR10 Ligand Cutaneous T Cell–attracting Chemokine (CTACK) in Lymphocyte Trafficking to Inflamed Skin (2001) (550)
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 (2012) (531)
RANTES and Monocyte Chemoattractant Protein–1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 Is Involved in Crescent Formation and Interstitial Fibrosis (1997) (521)
Glycosaminoglycans mediate cell surface oligomerization of chemokines. (1997) (518)
Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. (2005) (516)
Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity (1998) (440)
Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice (2004) (381)
Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. (2005) (352)
Cloning and Characterization of a Specific Receptor for the Novel CC Chemokine MIP-3α from Lung Dendritic Cells (1997) (307)
Overcoming hurdles in developing successful drugs targeting chemokine receptors (2011) (306)
HIV-1 Tat protein mimicry of chemokines. (1998) (304)
A Key Role for Cc Chemokine Receptor 4 in Lipopolysaccharide-Induced Endotoxic Shock (2000) (295)
Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice1 (2001) (281)
Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. (1999) (278)
Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Line (*) (1995) (277)
A chemokine receptor antagonist inhibits experimental breast tumor growth. (2003) (275)
Met‐RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment (1999) (268)
Kinetics of Eotaxin Generation and Its Relationship to Eosinophil Accumulation in Allergic Airways Disease: Analysis in a Guinea Pig Model In Vivo (1997) (265)
Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. (2000) (262)
Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. (2005) (259)
The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity* (2001) (247)
Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. (1997) (245)
A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5 (1993) (229)
Granzyme A is an interleukin 1 beta-converting enzyme (1995) (223)
Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. (1999) (221)
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. (2010) (215)
Identification of the Glycosaminoglycan Binding Site of the CC Chemokine, MCP-1 (2004) (207)
Differential Effects of CC Chemokines on CC Chemokine Receptor 5 (CCR5) Phosphorylation and Identification of Phosphorylation Sites on the CCR5 Carboxyl Terminus* (1999) (207)
Endocytosis and Recycling of the HIV Coreceptor Ccr5 (2000) (197)
Ticks produce highly selective chemokine binding proteins with antiinflammatory activity (2008) (194)
Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. (1997) (186)
Identification of a glycosaminoglycan binding surface on human interleukin-8. (1998) (183)
Chemokine blockers--therapeutics in the making? (2006) (177)
The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* (2003) (168)
Characterization of Sequence Determinants within the Carboxyl-terminal Domain of Chemokine Receptor CCR5 That Regulate Signaling and Receptor Internalization* (2001) (166)
Amino-terminally Modified RANTES Analogues Demonstrate Differential Effects on RANTES Receptors* (1999) (166)
The biological relevance of chemokine-proteoglycan interactions. (2006) (164)
Interference with Heparin Binding and Oligomerization Creates a Novel Anti-Inflammatory Strategy Targeting the Chemokine System (2004) (164)
Selectivity and antagonism of chemokine receptors (1996) (159)
The Chemokine RANTES Is a Crucial Mediator of the Progression from Acute to Chronic Colitis in the Rat1 (2001) (156)
TSG-6 Inhibits Neutrophil Migration via Direct Interaction with the Chemokine CXCL8 (2014) (152)
Neutrophil-Derived CCL3 Is Essential for the Rapid Recruitment of Dendritic Cells to the Site of Leishmania major Inoculation in Resistant Mice (2010) (149)
Chronic expression of monocyte chemoattractant protein‐1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice (2005) (145)
Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion (1999) (140)
Similarities and Differences in RANTES- and (AOP)-RANTES–triggered Signals: Implications for Chemotaxis (1999) (132)
Co‐receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands (2000) (130)
The CC chemokine antagonist Met‐RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3 (1997) (130)
C-C Chemokine Receptor 3 Antagonism by the β-Chemokine Macrophage Inflammatory Protein 4, a Property Strongly Enhanced by an Amino-Terminal Alanine-Methionine Swap1 (2000) (129)
Amelioration of rat adjuvant-induced arthritis by Met-RANTES. (2005) (129)
Definition, function and pathophysiological significance of chemokine receptors. (1998) (127)
A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice (2008) (126)
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. (2003) (121)
RANTES Activates Jak2 and Jak3 to Regulate Engagement of Multiple Signaling Pathways in T Cells* (2001) (120)
The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity (1999) (117)
Molecular Cloning and Characterization of a Highly Selective Chemokine-binding Protein from the Tick Rhipicephalus sanguineus* (2007) (116)
Anti-chemokine small molecule drugs: a promising future? (2010) (115)
Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. (2003) (112)
Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. (2003) (110)
Chemokine inhibition--why, when, where, which and how? (2004) (107)
Early application of Met-RANTES ameliorates chronic allograft nephropathy. (2002) (106)
Selective recruitment of Th2‐type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein‐II (2001) (105)
Kinetics of Chemokine–Glycosaminoglycan Interactions Control Neutrophil Migration into the Airspaces of the Lungs (2010) (105)
Inhibition of Monocyte Chemoattractant Protein-1 Ameliorates Rat Adjuvant-Induced Arthritis1 (2008) (102)
The three-dimensional solution structure of RANTES. (1995) (99)
Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. (2010) (97)
The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. (2004) (96)
Combined Blockade of the Chemokine Receptors CCR1 and CCR5 Attenuates Chronic Rejection (2004) (93)
Strategies for chemokine antagonists as therapeutics. (2003) (91)
Multi-faceted strategies to combat disease by interference with the chemokine system. (2005) (91)
CCL3/MIP‐1α is pro‐inflammatory in murine T cell‐mediated hepatitis by recruiting CCR1‐expressing CD4+ T cells to the liver (2004) (91)
Receptor-mediated Endocytosis of CC-chemokines* (1997) (90)
The strategy of blocking the chemokine system to combat disease (2000) (90)
HMGB 1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL 12 and signaling via CXCR 4 (2012) (89)
Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System (2017) (87)
Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. (2009) (87)
The X-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 Å resolution (1996) (85)
Differential Activation of CC Chemokine Receptors by AOP-RANTES* (2000) (85)
CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. (2007) (84)
Purification, cDNA cloning and heterologous expression of human phosphomannose isomerase. (1994) (83)
Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES (2002) (81)
Molecular cloning of murine CC CKR-4 and high affinity binding of chemokines to murine and human CC CKR-4. (1996) (80)
Mechanism of irreversible inactivation of phosphomannose isomerases by silver ions and flamazine. (1995) (77)
An engineered monomer of CCL2 has anti‐inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo (2008) (77)
Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro (2006) (76)
Single Administration of the CXC Chemokine-Binding Protein Evasin-3 During Ischemia Prevents Myocardial Reperfusion Injury in Mice (2010) (74)
CCL5-CCR5-mediated Apoptosis in T Cells (2006) (71)
Close Association of the First and Fourth Extracellular Domains of the Duffy Antigen/Receptor for Chemokines by a Disulfide Bond Is Required for Ligand Binding* (1997) (69)
Inhibition of Airway Inflammation by Amino-Terminally Modified RANTES/CC Chemokine Ligand 5 Analogues Is Not Mediated through CCR3 (2003) (68)
Mutation of Leu25 and Val27 Introduces CC Chemokine Activity into Interleukin-8 (*) (1995) (68)
PMI40, an intron-containing gene required for early steps in yeast mannosylation (1992) (68)
Characterization of the Chemokine CXCL11-Heparin Interaction Suggests Two Different Affinities for Glycosaminoglycans* (2010) (67)
Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by Glycosaminoglycans. (2019) (63)
Chemokine receptors--future therapeutic targets for HIV? (1999) (62)
Functional role of CCL5/RANTES for HCC progression during chronic liver disease. (2017) (60)
The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. (2013) (57)
Targeting chemokines: Pathogens can, why can't we? (2015) (56)
Current status of chemokine receptor inhibitors in development. (2012) (55)
Treatment with Evasin-3 Reduces Atherosclerotic Vulnerability for Ischemic Stroke, but Not Brain Injury in Mice (2013) (55)
Angiotensin II-Induced Mononuclear Leukocyte Interactions with Arteriolar and Venular Endothelium Are Mediated by the Release of Different CC Chemokines1 (2006) (55)
Identification of Key Charged Residues of Human Interleukin-5 in Receptor Binding and Cellular Activation (*) (1995) (54)
Modulation of Chemokine Responses: Synergy and Cooperativity (2016) (53)
Monoclonal antibodies as probes of conformational changes in protein-engineered cytochrome c. (1988) (52)
The chemokine system: novel broad-spectrum therapeutic targets. (2001) (52)
IL-3 Induces Down-Regulation of CCR3 Protein and mRNA in Human Eosinophils1 (2001) (52)
Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. (2009) (50)
Chemokine receptors - the new frontier for AIDS research. (1996) (50)
Therapeutic effects of evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis. (2011) (49)
The Interaction of Heparin Tetrasaccharides with Chemokine CCL5 Is Modulated by Sulfation Pattern and pH* (2015) (49)
Chapter 4. Interactions of chemokines with glycosaminoglycans. (2009) (48)
Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice (2013) (48)
Chemokines as targets for therapy. (2011) (47)
Chemokine receptors and their role in leukocyte activation. (1999) (45)
An Interleukin 5 Mutant Distinguishes between Two Functional Responses in Human Eosinophils (1997) (45)
The CCL3/Macrophage Inflammatory Protein-1α–Binding Protein Evasin-1 Protects from Graft-versus-Host Disease but Does Not Modify Graft-versus-Leukemia in Mice (2010) (45)
Glycosaminoglycan analogs as a novel anti-inflammatory strategy (2012) (44)
Interaction of the CC-Chemokine RANTES with Glycosaminoglycans Activates a p44/p42 Mitogen-Activated Protein Kinase-Dependent Signaling Pathway and Enhances Human Immunodeficiency Virus Type 1 Infectivity (2002) (44)
Plasma concentrations and role of macrophage inflammatory protein-1alpha during chronic Schistosoma mansoni infection in humans. (2002) (44)
Tissue-Specific Mechanisms Control the Retention of IL-8 in Lungs and Skin1 (2002) (44)
Treatment with Evasin‐3 abrogates neutrophil‐mediated inflammation in mouse acute pancreatitis (2014) (43)
Structural Basis of Chemokine Sequestration by a Tick Chemokine Binding Protein: The Crystal Structure of the Complex between Evasin-1 and CCL3 (2009) (43)
Substitutions engineered by chemical synthesis at three conserved sites in mitochondrial cytochrome c. Thermodynamic and functional consequences. (1989) (42)
Recombinant guinea pig and human RANTES activate macrophages but not eosinophils in the guinea pig. (1997) (42)
The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary disease. (2005) (41)
The CC Chemokine Receptor Antagonist Met–RANTES Inhibits Eosinophil Effector Functions (1999) (39)
Cyclic AMP stimulates a JunD/Fra-2 AP-1 complex and inhibits the proliferation of interleukin-6-dependent cell lines. (1995) (39)
A chimeric MIP‐1α/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors (2001) (39)
Stem Cell Factor-Induced Leukotriene B4 Production Cooperates with Eotaxin to Mediate the Recruitment of Eosinophils During Allergic Pleurisy in Mice1 (2001) (39)
Purification and characterization of fungal and mammalian phosphomannose isomerases (1994) (38)
In vitro and in vivo studies with purified recombinant human interleukin 5. (1990) (38)
Preparation and characterization of human interleukin-5 expressed in recombinant Escherichia coli. (1990) (37)
The use of chemokine antagonists in EAE models (2008) (36)
Modulation of antibody-mediated glomerular injury in vivo by interleukin-6. (1993) (36)
Chemokines bind to sulfatides as revealed by surface plasmon resonance. (2005) (36)
Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models (2013) (35)
The cytochrome c oxidase-cytochrome c complex: spectroscopic analysis of conformational changes in the protein-protein interaction domain. (1989) (32)
Protein therapeutics – lessons learned and a view of the future (2006) (31)
Phosphomannose isomerase from Saccharomyces cerevisiae contains two inhibitory metal ion binding sites. (1993) (31)
Purification of recombinant chemokines from E. coli. (2000) (31)
On the relationship between oxidation-reduction potential and biological activity in cytochrome c analogues. Results from four novel two-fragment complexes. (1987) (30)
CCR1 and CCR5 chemokine receptors are involved in fever induced by LPS (E. coli) and RANTES in rats (2007) (29)
The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance (2005) (28)
The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans (2013) (28)
Cloning and Characterization of a Novel Murine Macrophage Inflammatory Protein-1α Receptor* (1996) (28)
Evasins: Therapeutic Potential of a New Family of Chemokine-Binding Proteins from Ticks (2016) (27)
Structure and Bioactivity of Recombinant Human CTAP-III and NAP-2 (1997) (26)
Antagonism of the chemokine Ccl 5 ameliorates experimental liver fibrosis in mice (2010) (26)
Chemokine Cooperativity Is Caused by Competitive Glycosaminoglycan Binding (2014) (26)
CCL18 Exhibits a Regulatory Role through Inhibition of Receptor and Glycosaminoglycan Binding (2013) (26)
Met-RANTES Inhibition of Mucosal Perfusion Failure in Acute Intestinal Transplant Rejection – Role of Endothelial Cell-Leukocyte Interaction (2002) (26)
Chemokines and Glycosaminoglycans (2015) (25)
Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss (2009) (25)
A fluorescent interleukin-8 receptor probe produced by targetted labelling at the amino terminus. (1995) (25)
In vivo and in vitro folding of a recombinant metalloenzyme, phosphomannose isomerase. (1996) (24)
Multiple T cell antigenic determinants identified within a limited region of the horse cytochrome c molecule (1987) (24)
Selenomethionine labelling of phosphomannose isomerase changes its kinetic properties. (1995) (24)
A Molecular Switch of Chemokine Receptor Selectivity (1996) (24)
Relevance of CCL3/CCR5 axis in oral carcinogenesis. (2017) (23)
Identification of the Pharmacophore of the CC Chemokine-binding Proteins Evasin-1 and -4 Using Phage Display* (2014) (23)
Stem Cell Factor-Induced Leukotriene B4 Production Cooperates with Eotaxin to Mediate the Recruitment of Eosinophils During Allergic Pleurisy in Mice (2001) (23)
Is CCR2 the right chemokine receptor to target in rheumatoid arthritis? (2008) (21)
Evasins: Tick Salivary Proteins that Inhibit Mammalian Chemokines (2020) (21)
Two Distinct Signalling Pathways Are Involved in the Control of the Biphasic junB Transcription Induced by Interleukin-6 in the B Cell Hybridoma 7TD1 (*) (1995) (20)
Synthesis and evaluation of fluorescent chemokines labeled at the amino terminal. (1997) (20)
Selective binding and presentation of CCL5 by discrete tissue microenvironments during renal inflammation. (2007) (20)
Up-Regulation of CCR1 and CCR3 and Induction of Chemotaxis to CC Chemokines by IFN-g in Human (1999) (20)
Soluble interleukin-5 receptor alpha-chain binding assays: use for screening and analysis of interleukin-5 mutants. (1995) (19)
Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1. (1999) (19)
Purification, characterisation and crystallisation of selenomethionyl recombinant human interleukin-5 from Escherichia coli. (1993) (19)
The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function. (2009) (19)
Detection and identification of plasma proteins that bind GlialCAM using ProteinChip™ Arrays, SELDI‐TOF MS, and nano‐LC MS/MS (2008) (18)
Relevance of CCL3/CCR5 axis in oral carcinogenesis (2017) (18)
Conformation-directed recombination of enzyme-activated peptide fragments: a simple and efficient means to protein engineering. Its use in the creation of cytochrome c analogues for structure-function studies. (1989) (18)
Discovery of a novel series of CXCR3 antagonists. (2010) (18)
The x-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 angstrom resolution. (1996) (17)
Macrophage inflammatory protein-1alpha uses a novel receptor for primitive hemopoietic cell inhibition. (2001) (17)
Identification of Cys-150 in the active site of phosphomannose isomerase from Candida albicans. (1993) (16)
Quantitative detection of therapeutic proteins and their metabolites in serum using antibody-coupled ProteinChip Arrays and SELDI-TOF-MS. (2006) (16)
Enzyme-assisted semisynthesis of polypeptide active esters and their use. (1988) (16)
A knottin scaffold directs the CXC-chemokine–binding specificity of tick evasins (2019) (16)
Interference with Oligomerization and Glycosaminoglycan Binding of the Chemokine CCL5 Improves Experimental Liver Injury (2012) (15)
The chemokine family. Potential therapeutic targets from allergy to HIV infection. (1998) (15)
Drug discovery targeting the chemokine system--where are we? (2009) (14)
Identification of an Fe(III)-dihydroxyphenylalanine site in recombinant phosphomannose isomerase from Candida albicans. (1997) (14)
Molecular cloning and characterisation of a neutrophil chemotactic protein from porcine platelets. (1994) (12)
A new non-covalent complex of semisynthetically modified tryptic fragments of cytochrome c. (1986) (12)
The crystal structure of met-rantes: comparison with native rantes and aop-rantes (2000) (12)
Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. (2002) (12)
Inhibition of phosphomannose isomerase by mercury ions. (1994) (11)
Cloning and characterization of a novel murine macrophage inflammatory protein-1 alpha receptor. (1996) (11)
Cellular Assays of Chemokine Receptor Activation (2001) (10)
The Molecular Basis of Selectivity Between CC and CXC Chemokines: The Possibility of Chemokine Antagonists as Anti‐inflammatory Agents (1996) (10)
Properties of 7ND-CCL2 are modulated upon fusion to Fc. (2012) (10)
Semisynthesis of cytochrome c analogues. The effect of modifying the conserved residues 38 and 39. (1987) (9)
Aminooxypentane-RANTES induces CCR3 activation and internalization of CCR3 from the surface of human eosinophils. (2001) (8)
Crystallization and preliminary X-ray analysis of Candida albicans phosphomannose isomerase. (1994) (8)
Human interleukin-6: detection of 10 attomoles by colorimetric sandwich ELISA using immunopurified polyclonal anti-IL-6 antibodies. (1993) (8)
Strategies to interfere with the chemokine network in disease. (1999) (7)
Mice Chemokine Receptors CCR 2 and CCR 5 in Expression and Characterization of the Schlöndorff (2001) (7)
Crystallization and preliminary X-ray diffraction studies of recombinant human interleukin-5. (1993) (7)
Human interleukin-5 expressed in Escherichia coli has N-terminal modifications. (1992) (7)
A case of spurious product formation during attempted resynthesis of proteins by reverse proteolysis. Some batches of 'pure' glycerol contain cross-linking agents. (1984) (6)
Spatial Orientation of the α and βc Receptor Chain Binding Sites on Monomeric Human Interleukin-5 Constructs* (1997) (5)
The complete primary structure of glycosylated porcine platelet factor 4. (1995) (5)
Chemokine receptors and their antagonists in allergic lung disease (1999) (5)
Aminooxypentane-RANTES Induces CCR3 Activation and Internalization of CCR3 from the Surface of Human Eosinophils (2001) (5)
Viral macrophage inflammatory protein-II improves acute rejection in allogeneic rat kidney transplants (2010) (4)
[Reduction of acute kidney transplantation rejection by the chemokine receptor antagonist Met-RANTES]. (1999) (4)
Cloning and Characterization of a Novel Murine Macrophage Inflammatory Protein-1 (cid:97) Receptor* (1996) (4)
Chemokine receptors--the next therapeutic target for HIV? (2001) (4)
Chapter 2.2 – Chemokines (2002) (3)
Crystallization and preliminary X-ray diffraction studies of human RANTES. (1994) (2)
The carboxy-terminal region of human interleukin-5 is essential for maintenance of tertiary structure but not for dimerization (1996) (2)
Chemokine receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (2)
Mutagenesis by Phage Display. (2016) (1)
Targeting the Chemokine System (2003) (1)
Antagonism of Chemokine Receptors in Preventing Infection by HIV (1999) (1)
Editorial: Chemokines - beyond chemotaxis. (2018) (1)
Crystal Structure of human RANTES mutant K45E (2004) (1)
Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease (2012) (1)
Semisynthesis of a deletion mutant of cytochrome c by condensation of enzymatically activated fragments (1988) (1)
Structural Aspects of Chemokines and Their Interactions with Receptors and Glycosaminoglycans (2011) (1)
Chemokine receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database (2020) (1)
A chemokine receptor antagonist reduces the incidence and severity of collagen induced arthritis in DBA/1 mice (1997) (1)
ENZYME-ASSISTED SEMISYNTHESIS OF POLYPEPTIDE ACTIVE ESTERS FOR SUBSEQUENT SPONTANEOUS COUPLING (1987) (1)
The selective pharmacologic inhibition of CXC chemokines is associated with an improvement of histological features of vulnerability in mouse atherosclerotic plaques (2013) (0)
CS12-5. Which chemokine receptor should we target in Rheumatoid Arthritis (2011) (0)
CHEMOKINES, CC | RANTES (CCL5) (2006) (0)
Granzyme A Is an Interleukin 13-converting E n z y m e By (2003) (0)
Chemokine receptor antagonist development. (2013) (0)
Corrigendum to “CCR1 and CCR5 chemokine receptors are involved in fever induced by LPS (E. coli) and RANTES in rats” [Brain Res. 1161 (2007) 21–31] (2008) (0)
Function of Inducing Stimulus Use of Alternative Chemokine Receptors as a Resting and Inflamed Airway Epithelium : Regulation of Dendritic Cell Recruitment into (2001) (0)
Methods for the Recognition of GAG-Bound Chemokines. (2016) (0)
389 OLIGOMERIZATION AND GLYCOSAMINOGLYCAN BINDING OF THE CHEMOKINE CCL5 MEDIATES EXPERIMENTAL LIVER INJURY IN MICE (2012) (0)
Isolation of a lipid-soluble histamine release factor from human platelets. (1994) (0)
Both MIP-1α and RANTES and their receptors are expressed in murine vein grafts and aggravate vein graft remodeling (2008) (0)
Using cc-chemokine CCL5 / RANTES mutant for treatment of liver diseases (2003) (0)
CS6-2 What nature can teach us about chemokine function (2010) (0)
Selective Deletion of Heparan Sulfotransferase Enzyme, Ndst1, in Donor Endothelial and Myeloid Precursor Cells Significantly Decreases Acute Allograft Rejection (2018) (0)
Functional role of CCL5/RANTES for HCC progression during chronic liver disease: from humans to mice (2015) (0)
Crystal Structure of human RANTES mutant 44-AANA-47 (2004) (0)
in Human Neutrophils γ by IFN- Induction of Chemotaxis to CC Chemokines Up-Regulation of CCR1 and CCR3 and (2013) (0)
Chemokines and their receptors: their biology and therapeutic relevance (2012) (0)
Anti-Inflammatory Strategy Targeting the Oligomerization Creates a Novel Interference with Heparin Binding and (2017) (0)
Cytochrome c̱ Semisynthesis Using Enzymic Resynthesis Techniques (1983) (0)
Structure and activity of interleukin 5, a key mediator of asthmatic inflammation (1994) (0)
Chemokines as drug targets (2007) (0)
From Molecular Science to the Treatment of Allergy (1999) (0)
The effect of the chemokine antagonist Met-RANTES on human eosinophils (1998) (0)
Characterization of Chemokine Receptors (2001) (0)
Retention of IL-8 in Lungs and Skin Tissue-Specific Mechanisms Control the (2002) (0)
Protein and mRNA in Human Eosinophils IL-3 Induces Down-Regulation of CCR 3 Proudfoot and Jörn Elsner (2001) (0)
Swapan Amino-Terminal Alanine-Methionine Protein 4, a Property Strongly Enhanced by -Chemokine Macrophage Inflammatory b the C-C Chemokine Receptor 3 Antagonism by (0)
RANTES peptide fragments, and this, as well as containing compositions suitable for the treatment of inflammation (1997) (0)
Differential Activation of CC Chemokine Receptors by (2000) (0)
Competitive Glycosaminoglycan Binding Chemokine Cooperativity Is Caused by (2014) (0)
A novel strategy for blocking chemokine mediated inflammation (2003) (0)
ID: 75: Unraveling the properties required for an effective therapeutic antibody targeting a chemokine (2015) (0)
Mediated through CCR 3 Chemokine Ligand 5 Analogues Is Not Amino-Terminally Modified RANTES / CC Inhibition of Airway Inflammation by Offord and (2003) (0)
During Allergic Pleurisy in Mice Mediate the Recruitment of Eosinophils Production Cooperates with Eotaxin to 4 Stem Cell Factor-Induced Leukotriene B (2001) (0)
Candida Albicans Phosphomannose Isomerase (1997) (0)
Inhibiting the oligomerisation and glycosaminoglycan binding of the chemokine CCL5 reduces experimental liver injury in vivo (2012) (0)
Down-regulation of CC chemokine receptor 3 protein and mRNA in human eosinophils mediated by IL-3 (2002) (0)
Chronic Colitis in the Rat Mediator of the Progression from Acute to The Chemokine RANTES Is a Crucial (2000) (0)
O043 Treatment with chemokine-binding protein Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke in mice (2012) (0)
Where are we with anti-chemokine therapies? (2009) (0)
human RANTES complexed to heparin-derived disaccharide III-S (2004) (0)
HUMAN RANTES, NMR, 13 STRUCTURES (1996) (0)
CC Chemokine Receptor (CCR)4 and the CCR10 Ligand Cutaneous T Cell–attracting Chemokine (CTACK) in Lymphocyte Trafﬁcking to Inﬂamed Skin (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Amanda Elizabeth Inn Proudfoot?

Amanda Elizabeth Inn Proudfoot is affiliated with the following schools:

Amanda Elizabeth Inn Proudfoot's Academic­Influence.com Rankings

Amanda Elizabeth Inn Proudfoot's Degrees

Why Is Amanda Elizabeth Inn Proudfoot Influential?

Amanda Elizabeth Inn Proudfoot's Published Works

Published Works

What Schools Are Affiliated With Amanda Elizabeth Inn Proudfoot?

Amanda Elizabeth Inn Proudfoot's AcademicInfluence.com Rankings